Methylprednisolone for COVID-19 Treatment

Once eligibility had been confirmed (24–48 h after hospitalisation), the patients were randomly allocated to control (n=34) and intervention (n=34) groups in a 1:1 ratio by the block randomisation method. Patients were allocated to either receive methylprednisolone pulse (intravenous injection, 250 mg·day⁻¹ for 3 days) or not receive methylprednisolone/other glucocorticoids. All patients received standard care (hydroxychloroquine sulfate, lopinavir and naproxen) for COVID-19 according to the protocol for diagnosis and treatment of COVID-19 in Iran. Patients were blinded to the treatment group. Physicians and clinician teams knew about the medicine and intervention groups. Due to the emergency nature of this trial, placebos of methylprednisolone were not prepared.

Free full text: Click here

Edalatifard M., Akhtari M., Salehi M., Naderi Z., Jamshidi A., Mostafaei S., Najafizadeh S.R., Farhadi E., Jalili N., Esfahani M., Rahimi B., Kazemzadeh H., Mahmoodi Aliabadi M., Ghazanfari T., Sattarian M., Ebrahimi Louyeh H., Raeeskarami S.R., Jamalimoghadamsiahkali S., Khajavirad N., Mahmoudi M, & Rostamian A. (2020). Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. The European Respiratory Journal, 56(6), 2002808.

Publication 2020

Covid 19 Diagnosis Eligibility Emergency Glucocorticoids Hydroxychloroquine sulfate Lopinavir Medicine Methylprednisolone Naproxen Patients Physicians Placebos Pulse

Corresponding Organization :

Other organizations : Zero to Three, Tehran University of Medical Sciences, Isfahan University of Medical Sciences, Kermanshah University of Medical Sciences, Imam Khomeini Hospital, Zanjan University of Medical Sciences, Shahed University

Top 5 similar protocols

Protocol cited in 7 other protocols

Variable analysis

independent variables

Receiving methylprednisolone pulse (intravenous injection, 250 mg·day^{-1} for 3 days)

dependent variables

Clinical outcomes

control variables

Standard care (hydroxychloroquine sulfate, lopinavir and naproxen) for COVID-19 according to the protocol for diagnosis and treatment of COVID-19 in Iran

controls

Positive control: Patients receiving standard care for COVID-19
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!